Inclusion Criteria:

1. Patients ≥ 18 years of age.

2. Patients diagnosed with recurrent or de novo, locally advanced (unresectable) or
metastatic adenocarcinoma of the colon.

3. K-ras mutation status.

4. Planned treatment of and naive for oxaliplatin plus fluorouracil/leucovorin (FOLFOX)
in combination with bevacizumab (bvz).

5. At least one evaluable site of disease according to RECIST criteria.

6. ECOG Performance status 0, 1, or 2

7. Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN or GFR ≥ 50ml/min

8. Adequate hematopoietic function [white blood cell (WBC) count ≥ 3000/μl, absolute
neutrophil count (ANC) ≥1500/μl, platelets ≥100 000/μl, haemoglobin level ≥ 9.0 g/dl]

9. Adequate end organ function, defined as the following: total bilirubin < 1.5 x ULN,
SGOT and SGPT < 3.0 x ULN (in case of liver metastases SGOT and SGPT < 5.0 x ULN)

10. Ability to give signed informed consent prior to any screening procedures

11. Tissue obtained from archive and/or during a standard resection or biopsy procedure.

Exclusion Criteria:

1. Patient has received any other investigational product within 28 days of first day of
study drug dosing

2. Patients having familial and/or hereditary CRC

3. CRC associated with ulcerative colitis

4. Patient with any significant history of non-compliance to medical regimens or with
inability to grant reliable informed consent.